MABXIENCE RESEARCH SL.
Location
Madrid
Founded
2015-12-23
Website
Risk Signals
16 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about MABXIENCE RESEARCH SL.
Live alerts from global media, monitored by Business Radar
2025-05-26 (pharmasource.global)
mAbxience Signs Licensing Deal with Abiogen Pharma -
mAbxience, a Fresenius Kabi majority-owned CDMO with additional ownership from Insud Pharma, has entered a strategic licensing agreement with Italy-based Abiogen Pharma to develop and…
Read more
2025-05-26 (informatori.it)
Abogen and Mabxience together to bring a new biosimilar to Italy <
Abiogen Pharma and Mabxience have announced the signature of a strategic agreement for the marketing in Italy of a biosimilar candidate. According to the terms, abogen will manage marketing and distribution on… Continued
Read more
2025-05-15 (novaciencia.es)
The Biohackathon of the ULE connects companies and students to face the challenges of the future
Half a hundred students face the three challenges raised by the pharmaceutical
Read more
2025-04-26 (heraldodeleon.es)
León adds 60 million in investment and is consolidated as the third biotechnological pole
The investment dynamism of Mabxience, Curia, Syva, León Research and other firms reinforces the industrial, researcher and sanitary muscle of the province
Read more
2025-03-04 (businesswire.com)
Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
Read more
2024-10-04 (citeline.com)
Keytruda? Opdivo? Teva And mAbxience Broaden Partnership With PD-1 Biosimilar
Teva is continuing along its well-trodden path of partnered biosimilar assets, striking a further agreement with Spanish develop mAbxience that could be for the development of either pembrolizumab or nivolumab.
Read more
2024-10-03 (contractpharma.com)
Teva, mAbxience Expand Collaboration to Include an Additional Oncology Biosimilar |
Aim to provide cost-effective, high-quality biosimilar treatments that address critical unmet needs in oncology care.
Read more
2024-04-04 (fiercepharma.com)
Teva, forging ahead with new strategy, inks biosimilar deal with Spain's mAbxience
As Teva advances its Pivot to Growth strategy under CEO Richard Francis, the company is making good on its pledge to beef up its biosimilar pipeline through outside deals. | Teva has unveiled a fresh in-licensing accord with Spain’ s mAbxience to chip in on an investigational biosimilar spanning
Read more
2024-02-07 (contractpharma.com)
mAbxience and Biosidus Enter CDMO Agreement |
mAbxience will manufacture the active ingredient Agalsidase Beta, developed by Biosidus as a biosimilar of Fabrazyme for the treatment of Fabry disease.
Read more
2023-12-25 (indiatimes.com)
Intas Pharmaceuticals Ltd. Announces Licensing Agreement with mAbxience
Intas Pharmaceuticals Ltd. Announces Licensing Agreement with mAbxience for Etanercept Biosimilar Targeting Autoimmune Diseases in more than 150 Countries, including Europe and the United States of America.
Read more
2023-09-21 (contractpharma.com)
Abbott Labs, mAbxience Enter Biosimilars Mfg. Pact |
mAbxience will manufacture the biosimilars at its GMP approved facilities in Spain and Argentina.
Read more
2023-09-20 (nasdaq.com)
Abbott Inks Deal With MAbxience To Commercialize Biosimilar Molecules In Emerging Markets
(RTTNews) - Abbott Laboratories (ABT) announced Wednesday an agreement with Spain-based global biotech firm mAbxience Holdings S.L. to commercialize several biosimilars focusing on oncology, women's health and respiratory diseases in emerging markets.
Read more